GeneCapture

GeneCapture is pioneering a rapid, portable diagnostic platform designed to identify pathogens and determine antibiotic susceptibility in under two hours at the point of care. Its core technology, The CAPTURE Platform™, uses direct RNA hybridization (DRH) on a disposable cartridge to detect bacteria, viruses, fungi, and parasites without nucleic acid amplification (PCR). Targeting applications in clinical, community, agricultural, and military settings, the company aims to combat antimicrobial resistance and improve patient outcomes by providing actionable diagnostic data outside traditional lab environments. The platform is in development, with backing from entities like the Defense Health Agency.

The CAPTURE Platform™: A portable, cartridge-based system using Direct RNA Hybridization (DRH) on a microarray to identify pathogens from unamplified RNA within one hour, followed by a separate cartridge for rapid Antibiotic Susceptibility Testing (AST) using lyophilized antibiotics and growth measurement.

GeneCapture competes in the rapid diagnostic and AST space against large players like bioMérieux (BioFire FilmArray), Becton Dickinson (BD Kiestra), and Abbott, as well as other molecular diagnostic startups. Its key differentiators are the combined ID/AST in ~2 hours without PCR or refrigeration, and its highly portable form factor designed for true point-of-care use.